Vaccines Against Infectious Diseases – VID
The Vaccines Against Infectious Diseases (VID) study section reviews applications concerned with vaccine late-stage development against all classes of pathogens. A feature of applications reviewed in this study section is the measurement of vaccine efficacy. This study section also reviews applications focusing on the improvement and safety of vaccines already approved for human or veterinary use. Applications often involve animal models, human samples, or human subjects.
Review Dates
Topics
- Vaccines against pathogens of clinical or veterinary interest, including bacteria, viruses, parasites, fungi, bacterial toxins, and pathogenic agents that have biodefense implications
- Pre-clinical and clinical vaccine testing, including protection from disease, and safety studies
- Vaccine formulation and production for all classes of vaccines (inactivated vaccines, live-attenuated vaccines, mRNA vaccines, toxoid vaccines, viral vector vaccines, and subunit, recombinant, polysaccharide, and conjugate vaccines).
- Vaccine platform and delivery systems optimization
- Safety studies and modifications of existing vaccines
Shared Interests and Overlaps
- There are shared interests with Early Development of Vaccine against Infectious Diseases [DCAI (89)]. Applications that emphasize early to mid-stage development of vaccines or aim to characterize vaccine-induced immune responses may be reviewed in DCAI (89). Applications that emphasize late-stage development and measure vaccine efficacy, safety, or improvement may be reviewed in VID.
- There are shared interests in nucleic acid-based vaccine development with Drug and Biologic Therapeutic Delivery (DBTD) and Nucleic Acid Therapeutic Delivery [DDTD (81)]. Applications that emphasize novel methods for vaccine delivery, with a focus on bioengineering principles, may be reviewed in DBTD or DDTD (81). Applications that emphasize vaccine testing and efficacy may be reviewed in VID.
- There are shared interests in studies of vaccines approved for human use with Etiology, Diagnostic, Intervention and Treatment of Infectious Diseases (EDIT). Applications that focus on mechanisms of vaccine efficacy may be reviewed in EDIT. Applications that focus on vaccine safety or on modifying the composition of existing vaccines may be reviewed in VID.
- There are shared interests with Immunobiology of Transplantation and Alloimmunity (ITA). Applications that focus on the impact of immunosuppressive therapies on immune responses to vaccine and/or vaccine performance may be reviewed in ITA. Applications that focus on general approaches to improve the performance of existing vaccines may be reviewed in VID.
- There are shared interests with Bacterial Innate Immunomodulation and Pathogenesis (IIDC (81)) in the interplay of innate processes and memory immunity to bacterial infections. Applications that emphasize measurement of vaccine efficacy as the endpoint may be reviewed in VID. Studies focused on prior exposure to infection or direct bacterial modulation of innate immune responses and how the innate response contributes to infection-related disease pathogenesis may be reviewed by IIDC (81).
